9 Results for "

PD-L1 binding peptide

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "PD-L1 binding peptide" in MCE Product Catalog:

Cat. No.: HY-P3440
CAS No.: 1886057-64-2
Research Areas:  

Cancer

WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .
loading...
    loading...
Cat. No.: HY-103048A
Purity:  99.34%
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
loading...
    loading...
Cat. No.: HY-P2478
CAS No.: 2815311-61-4
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 .
loading...
    loading...
Cat. No.: HY-P11110
CAS No.: 2222260-53-7
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

RK-10 is a PD-L1 binding peptide. RK-10 conjugated with Cy5 (HY-D0821) or Biotin (HY-B0511) can used to detect PD-L1 expressing tumors with flow cytometry or immunohistochemistry. RK-10 can be used for cancers like NSCLC, breast cancer, squamous cell carcinoma and melanoma detection research .
loading...
    loading...
Cat. No.: HY-P10978
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( 68Ga and 18F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC50 value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-103048
CAS No.: 1629654-95-0
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .
loading...
    loading...
Cat. No.: HY-P2478A
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 .
loading...
    loading...
Cat. No.: HY-P2474
CAS No.: 2135542-86-6
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 .
loading...
    loading...
Cat. No.: HY-P3440A
CAS No.: 2767203-39-2
Research Areas:  

Cancer

NOTA-WL12 is a conjugate of WL12 (HY-P3440) (peptide targeting PD-L1) and NOTA (HY-134418) (chelate). NOTA-WL12 shows high binding affinity to the PD-L1 (KD = 3.012 nM). NOTA-WL12 can be labeled with radioactive isotopes for tumor imaging .
loading...
    loading...